AP Biosciences Inc (6945.TWO)
- Previous Close
53.40 - Open
53.60 - Bid 52.80 x --
- Ask 53.60 x --
- Day's Range
52.60 - 53.70 - 52 Week Range
36.45 - 61.40 - Volume
30,009 - Avg. Volume
46,407 - Market Cap (intraday)
4.562B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-5.61 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
AP Biosciences Inc, a clinical-stage biopharmaceutical company, researches and develops bispecific antibody drugs for unmet medical needs. It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinomas; AP402, which is in in the pre-clinical research phase for breast cancer patients; and AP601 that is in pre-clinical research phase for treating lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors. The company was founded in 2013 and is based in Taipei City, Taiwan.
www.apbioinc.comRecent News: 6945.TWO
View MorePerformance Overview: 6945.TWO
Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6945.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6945.TWO
View MoreValuation Measures
Market Cap
4.55B
Enterprise Value
3.07B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.80
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-19.07%
Return on Equity (ttm)
-32.20%
Revenue (ttm)
32.25M
Net Income Avi to Common (ttm)
-447.48M
Diluted EPS (ttm)
-5.61
Balance Sheet and Cash Flow
Total Cash (mrq)
1.74B
Total Debt/Equity (mrq)
4.28%
Levered Free Cash Flow (ttm)
-263.32M